Literature DB >> 21840512

Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.

Xu Yue1, Torsten Falk, Leslie A Zuniga, Lajos Szabò, Frank Porreca, Robin Polt, Scott J Sherman.   

Abstract

In Parkinson's disease (PD), the consequence of dopaminergic denervation is an imbalance in the activity of the direct and indirect striatofugal pathways, which include potentially important changes in opioid peptide expression and/or activity. The systemic administration of a novel glycosylated opioid peptide MMP-2200 (a.k.a. lactomorphin) was shown to have potent effects in two standard models of PD: 1) amphetamine-induced rotations in the hemi-Parkinsonian 6-hydroxydopamine (6-OHDA)-treated rat and 2) locomotion in the reserpine-treated rat. MMP-2200, an opioid mu and delta receptor agonist, reduced amphetamine-induced rotations in severely-lesioned hemi-Parkinsonian rats; this effect was fully blocked by naloxone, an opioid receptor antagonist. The selective δ-opioid receptor antagonist naltrindole only partially blocked the effect of MMP-2200. MMP-2200 alone did not induce rotations. This effect was also observed in a mild progressive rat 6-OHDA-lesion model. In animals treated with reserpine, profound akinesia was induced that was reversed with apomorphine. There was a prominent overshoot in animals that received apomorphine compared to non-reserpine treated animals, reflecting the well described phenomenon of dopamine supersensitivity indicating that apomorphine not only reversed akinesia but also induced hyper-kinesia. The opioid peptide MMP-2200 blocked the apomorphine-induced hyper-kinesia. This effect of MMP-2200 was prevented by pre-administration of naloxone. MMP-2200 had no effect in preventing the reserpine-induced akinesia, nor did it affect locomotion in control animals. Taken together, the results from these two models are consistent with the glycopeptide opioid agonist MMP-2200 having a potent effect on movements related to dopaminergic hyper-stimulation following striatal dopamine depletion that are best explained by a reduction in the downstream effects of dopamine agonists in these models.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840512      PMCID: PMC3167001          DOI: 10.1016/j.brainres.2011.07.038

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  39 in total

Review 1.  Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.

Authors:  Susan H Fox; Anthony E Lang; Jonathan M Brotchie
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

Review 2.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

3.  Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression.

Authors:  S Duty; J M Brotchie
Journal:  Exp Neurol       Date:  1997-04       Impact factor: 5.330

4.  Opioids and motor complications in Parkinson's disease.

Authors:  Pershia Samadi; Paul J Bédard; Claude Rouillard
Journal:  Trends Pharmacol Sci       Date:  2006-09-05       Impact factor: 14.819

5.  Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

Authors:  B Henry; A R Crossman; J M Brotchie
Journal:  Exp Neurol       Date:  1999-02       Impact factor: 5.330

Review 6.  Toxin-induced models of Parkinson's disease.

Authors:  Jordi Bové; Delphine Prou; Céline Perier; Serge Przedborski
Journal:  NeuroRx       Date:  2005-07

7.  Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.

Authors:  O Rascol; N Fabre; O Blin; J Poulik; U Sabatini; J M Senard; M Ané; J L Montastruc; A Rascol
Journal:  Mov Disord       Date:  1994-07       Impact factor: 10.338

8.  Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease.

Authors:  A P Nisbet; O J Foster; A Kingsbury; D J Eve; S E Daniel; C D Marsden; A J Lees
Journal:  Neuroscience       Date:  1995-05       Impact factor: 3.590

9.  L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.

Authors:  M A Cenci; C S Lee; A Björklund
Journal:  Eur J Neurosci       Date:  1998-08       Impact factor: 3.386

10.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

Authors:  H Sauer; W H Oertel
Journal:  Neuroscience       Date:  1994-03       Impact factor: 3.590

View more
  8 in total

Review 1.  Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.

Authors:  Yingxue Li; Mark R Lefever; Dhanasekaran Muthu; Jean M Bidlack; Edward J Bilsky; Robin Polt
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.

Authors:  Omar S Mabrouk; Torsten Falk; Scott J Sherman; Robert T Kennedy; Robin Polt
Journal:  Neurosci Lett       Date:  2012-11-02       Impact factor: 3.046

3.  Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.

Authors:  Mitchell J Bartlett; Ria M Joseph; Lindsey M LePoidevin; Kate L Parent; Nicholas D Laude; Levi B Lazarus; Michael L Heien; Miguel Estevez; Scott J Sherman; Torsten Falk
Journal:  Neurosci Lett       Date:  2015-11-28       Impact factor: 3.046

Review 4.  CNS active O-linked glycopeptides.

Authors:  Evan M Jones; Robin Polt
Journal:  Front Chem       Date:  2015-06-24       Impact factor: 5.221

5.  The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia.

Authors:  Mitchell J Bartlett; Omar S Mabrouk; Lajos Szabò; Andrew J Flores; Kate L Parent; Jean M Bidlack; Michael L Heien; Robert T Kennedy; Robin Polt; Scott J Sherman; Torsten Falk
Journal:  Int J Mol Sci       Date:  2020-12-22       Impact factor: 5.923

6.  Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism.

Authors:  Christopher R Apostol; Kelsey Bernard; Parthasaradhireddy Tanguturi; Gabriella Molnar; Mitchell J Bartlett; Lajos Szabò; Chenxi Liu; J Bryce Ortiz; Maha Saber; Katherine R Giordano; Tabitha R F Green; James Melvin; Helena W Morrison; Lalitha Madhavan; Rachel K Rowe; John M Streicher; Michael L Heien; Torsten Falk; Robin Polt
Journal:  Front Drug Discov (Lausanne)       Date:  2022-01-14

Review 7.  Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease.

Authors:  Carla Ferreira; Catarina Almeida; Sandra Tenreiro; Alexandre Quintas
Journal:  Life (Basel)       Date:  2020-06-11

8.  δ-opioid receptor activation protects against Parkinson's disease-related mitochondrial dysfunction by enhancing PINK1/Parkin-dependent mitophagy.

Authors:  Yuan Xu; Feng Zhi; Jiahao Mao; Ya Peng; Naiyuan Shao; Gianfranco Balboni; Yilin Yang; Ying Xia
Journal:  Aging (Albany NY)       Date:  2020-11-10       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.